Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-09-24, Stock:NVS, The news for the past five days is as follows:
2019-09-17: NEWS1: Novartis Announces New Data on Spondylitis Drug Cosentyx.NEWS2: J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis.NEWS3: Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck.NEWS4: Is Novartis (NVS) a Great Value Stock Right Now?.NEWS5: The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study.NEWS6: Alcon Finance Corporation -- Moody's assigns Baa2 ratings to Alcon Finance Corporation's new notes.
2019-09-18: NEWS1: Novartis halts distribution of generic heartburn medication.NEWS2: Distribution of heartburn drug Zantac halted over possible carcinogen.NEWS3: ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS4: Novartis halts distribution of its Zantac versions amid probe into impurities.NEWS5: After Boston speech, Ex-FDA chief defends record on vaping in interview.
2019-09-19: NEWS1: Biogen's New Study to Test Higher Dose of SMA Drug Spinraza.NEWS2: Novartis has halted distribution of generic Zantac. Here's what you need to know..NEWS3: The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO.NEWS4: British baby's death not due to SMA gene therapy -- Novartis.
2019-09-20: NEWS1: Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates.
2019-09-23: NEWS1: Investors May Want to Follow the Progress of These Biotechs.NEWS2: 6 Guru Stocks Beating the Market.NEWS3: Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval.NEWS4: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG.

Answer: Decrease